Literature DB >> 3137252

The influence of diabetes mellitus on thyrotropin response to thyrotropin-releasing hormone in untreated acromegalic patients.

C Shigemasa1, K Abe, S Taniguchi, Y Mitani, Y Ueta, T Adachi, K Urabe, T Tanaka, A Yoshida, T Hori.   

Abstract

Impairment of thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH) has been documented in patients with uncontrolled diabetes mellitus (DM). In acromegalic patients, however, there have been no data regarding TSH secretion studied taking the existence of DM into consideration. Therefore, we investigated the TSH response to TRH [expressed as TSH increment (delta TSH)] in 14 untreated acromegalic patients, who did not show the suprasellar extension of adenoma, divided into two groups on the basis of either presence or absence of uncontrolled DM, and in 28 normal subjects. The mean max delta TSH was significantly reduced (p less than 0.02) in acromegalic patients despite similar mean serum T4 and free T4 index (FT4l) levels. Furthermore, the mean basal and max delta TSH in 7 patients with DM (FBS, 120-300 mg/dl; HbA1, 8.8-15.2%) were significantly lower than those in 7 patients without DM (p less than 0.05 and p less than 0.02, respectively) despite similar the mean serum T3, T4, FT4l, growth hormone (GH) and prolactin (PRL) levels and sellar volume. In 4 patients with DM the TSH response to TRH 6-8 weeks after insulin therapy, when their HbA1 levels were normal, increased compared to that before insulin therapy. The mean max delta TSH after selective adenomectomy in 8 patients (3 in DM group and 5 in non-DM group), whose fasting basal GH fell to less than 5 ng/ml, was almost identical to that in normal subjects. In conclusion, the present study suggests that the abnormality in TSH secretion in acromegalic patients may be increased by the existence of uncontrolled DM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137252     DOI: 10.1007/BF03350145

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  The volume of the sella turcica.

Authors:  G DI CHIRO; K B NELSON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-06

2.  The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus.

Authors:  R Hall; B J Ormston; G M Besser; R J Cryer
Journal:  Lancet       Date:  1972-04-08       Impact factor: 79.321

3.  Stimulation of thyroid adenylate cyclase activity by sera from patients with non-thyroidal illness.

Authors:  F Kakezono; S Yamashita; N Yokoyama; S Morita; I Kubo; S Ohtakara; S Okamoto; I Morimoto; N Ikari; M Izumi
Journal:  Acta Endocrinol (Copenh)       Date:  1986-11

4.  Impaired pituitary thyrotroph function in uncontrolled type II diabetes mellitus: normalization on recovery.

Authors:  U M Kabadi
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

5.  Hypothalamic-pituitary-thyroid axis in acromegaly.

Authors:  E Carmina; F Rosato; S Pirronello; A Jannì
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256

6.  Impaired 3,5,3'-triiodothyronine (T3) production in diabetic patients.

Authors:  C S Pittman; A K Suda; J B Chambers; G Y Ray
Journal:  Metabolism       Date:  1979-04       Impact factor: 8.694

7.  Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.

Authors:  M F Scanlon; M D Rodriguez-Arnao; A M McGregor; D Weightman; M Lewis; D B Cook; A Gomez-Pan; R Hall
Journal:  Clin Endocrinol (Oxf)       Date:  1981-02       Impact factor: 3.478

8.  Normalization of thyroid stimulating hormone levels in acromegalic patients after selective adenomectomy.

Authors:  H Tsuchiya; T Onishi; S Mori; S Lee; H Kohno; S Imanaka; Y Saitoh; H Mogami; T Uozumi; Y Kumahara
Journal:  Endocrinol Jpn       Date:  1984-12

9.  Evidence for increased dopaminergic inhibition of secretion of thyroid-stimulating hormone in hyperprolactinemic patients with pituitary microadenoma.

Authors:  M E Quigley; S S Yen
Journal:  Am J Obstet Gynecol       Date:  1980-07-15       Impact factor: 8.661

10.  Increased thyroid-stimulating hormone response to thyrotropin-releasing hormone in hyperprolactinemic women.

Authors:  K Seki; K Kato
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

View more
  1 in total

1.  The impact of type I diabetes on rat liver gamma-glutamyltranspeptidase.

Authors:  S J Hemmings; R D Pekush
Journal:  Mol Cell Biochem       Date:  1994-10-26       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.